Get informed when a big investor buys or sells
+ FollowOctober 30, 2026 - AI Summary
Overvalued by 108.6% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $959.61 Million |
|---|---|
| Enterprise Value | $36.30 Billion |
| Earnings per Share | $-138.8 |
| Beta | 0.22 |
| Outstanding Shares | 91,391,315 |
| P/E Ratio | -30.31 |
|---|---|
| PEG | 21.13 |
| Price to Sales | 0.03 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 1.02 |
| Enterprise Value to EBIT | 7.48 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 1.43 |
| Debt to Equity | 0.81 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple int...